Joshua H. Bilenker, President & CEO at Loxo Oncology, Inc. (LOXO), sold 45,392 shares at $177.44 ($8.1M) on 2018-06-19, disclosed to the SEC on 2018-06-21.
Open-market sale of $8.1M LOXO by President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $176.20 | 2,336 | $412K | 5.1% |
| 2 | $177.06 | 3,427 | $607K | 7.5% |
| 3 | $177.44 | 8,232 | $1.5M | 18.1% |
| 4 | $177.44 | 8,232 | $1.5M | 18.1% |
| 5 | $178.12 | 1,737 | $309K | 3.8% |
| 6 | $178.30 | 8,763 |
| $1.6M |
| 19.3% |
| 7 | $178.30 | 8,763 | $1.6M | 19.3% |
| 8 | $179.83 | 3,902 | $702K | 8.7% |
| Total | $177.91 avg | 45,392 | $8.1M | 100% |
| Filing → |
| LOXO | SELL | 2018-12-12 | $2.7M | — | Filing → |
| LOXO | SELL | 2018-12-12 | $1.0M | — | Filing → |
| LOXO | SELL | 2018-11-28 | $1.2M | — | Filing → |